Atossa Therapeutics (NASDAQ:ATOS) Downgraded to “Sell” Rating by StockNews.com

StockNews.com cut shares of Atossa Therapeutics (NASDAQ:ATOS) from a hold rating to a sell rating in a research note published on Friday morning.

Other analysts also recently issued reports about the company. Ascendiant Capital Markets raised their price target on Atossa Therapeutics from $6.25 to $6.50 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Atossa Therapeutics in a research report on Thursday, October 31st.

Atossa Therapeutics Trading Up 8.0 %

Shares of NASDAQ:ATOS opened at $1.62 on Friday. The firm’s 50 day moving average price is $1.44 and its 200-day moving average price is $1.38. Atossa Therapeutics has a twelve month low of $0.62 and a twelve month high of $2.31.

Atossa Therapeutics (NASDAQ:ATOS) last released its earnings results on Monday, August 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. As a group, analysts predict that Atossa Therapeutics will post -0.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Therapeutics

Several institutional investors have recently made changes to their positions in ATOS. XTX Topco Ltd purchased a new position in Atossa Therapeutics in the second quarter valued at about $29,000. Intech Investment Management LLC purchased a new position in Atossa Therapeutics in the third quarter valued at about $29,000. SG Americas Securities LLC grew its stake in Atossa Therapeutics by 254.3% in the third quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares during the last quarter. Cetera Advisors LLC purchased a new position in Atossa Therapeutics in the first quarter valued at about $72,000. Finally, Virtu Financial LLC purchased a new position in Atossa Therapeutics in the first quarter valued at about $151,000. Hedge funds and other institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.